Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Vaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against COVID-19 will be priced at Rs 600 per shot for eligible individuals.
SII CEO Adar Poonawalla also welcomed the government’s move to allow precaution dose of the vaccine to all aged above 18 years at private vaccination centres, saying it will further provide long-term protection against the virus, and aid ease of travel.
“End-users will pay Rs 600 for the booster dose and the hospitals will get at discounted price,” Poonawalla said in a statement.
The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.
Reacting to the government’s decision in a tweet, Poonawalla said, "We are delighted by GOI’s announcement on booster. The decision will further provide long term protection and aid ease of travel." He, however, said the nine-month gap was a bit long although the company had 200 million dosages in stock. SII has the capacity to produce 4 billion dosages.
Poonawalla also exuded confidence that the whole country can be vaccinated in about three months in case of requirement in future.
SII and Bharat Biotech have been major suppliers of COVID-19 vaccines to the government so far.
Earlier in the day, he had stated that the booster dose should be made available to the public, saying it would help in protecting against the virus in future besides helping Indians overcome restrictions while travelling abroad.
In a tweet responding to a user, who highlighted difficulties faced by Indians travelling abroad who got their second dose in April 2021, Poonawalla had said,”I agree with you & sympathise for the inconvenience, boosters now should be made available to the public as a CHOICE.” He further said GoI “has done a fantastic job, protecting our nation with two doses, but in the context of future protection and travel restrictions, boosters will be useful”.
According to the health ministry, so far, about 96 per cent of all those above the age of 15 years in India have received at least one vaccine dose, while about 83 per cent have received both doses.
More than 2.4 crore precaution doses have also been administered to healthcare workers, frontline workers and those aged above 60 years. Besides, 45 per cent of beneficiaries in the 12-14 years age group have received the first dose, the ministry said.
The ongoing free COVID-19 inoculation programme through government vaccination centres for the first and the second dose to the eligible population as well as the precaution dose to healthcare workers, frontline workers and those above 60 years will be accelerated, the ministry stated.

Covishield booster dose priced at Rs 600 per shot: Serum Institute CEO Adar Poonawalla

Reacting to the government’s decision in a tweet, Poonawalla however, said the nine-month gap was a bit long although the company had 200 million dosages in stock

Vaccine maker Serum Institute of India has said the precaution dose of its Covishield vaccine against Covid-19 will be priced at Rs 600 per shot for eligible individuals.
SII CEO Adar Poonawalla also welcomed the government&rsquo;s move to allow precaution dose of the vaccine to all aged above 18 years at private vaccination centres, saying it will further provide long-term protection against the virus, and aid ease of travel.
The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.
Reacting to the government&rsquo;s decision in a tweet, Poonawalla&nbsp;however, said the nine-month gap was a bit long although the company had 200 million dosages in stock. SII has the capacity to produce 4 billion dosages.
Poonawalla also exuded confidence that the whole country can be vaccinated in about three months in case of requirement in future.
SII and Bharat Biotech have been major suppliers of Covid-19 vaccines to the government so far.
&nbsp;

Reacting to the government&rsquo;s decision in a tweet, Poonawalla&nbsp;however, said the nine-month gap was a bit long although the company had 200 million dosages in stock

Vaccine maker Serum Institute of India (SII) on Friday said the precaution dose of its Covishield vaccine against COVID-19 will be priced at Rs 600 per shot for eligible individuals.
<a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">SII CEO Adar Poonawalla</a> also welcomed the government&rsquo;s move to allow precaution dose of the vaccine to all aged above 18 years at private vaccination centres, saying it will further provide long-term protection against the virus, and aid ease of travel.
&ldquo;End-users will pay Rs 600 for the booster dose and the hospitals will get at discounted price,&rdquo; Poonawalla said in a statement.
The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.
Reacting to the government&rsquo;s decision in a tweet, Poonawalla said, "We are delighted by GOI&rsquo;s announcement on booster. The decision will further provide long term protection and aid ease of travel." He, however, said the nine-month gap was a bit long although the company had 200 million dosages in stock. SII has the capacity to produce 4 billion dosages.
Poonawalla also exuded confidence that the whole country can be vaccinated in about three months in case of requirement in future.
WATCH:&nbsp;<a title="Healthy eating: Immunity boosting summer foods to incorporate into your diethttps://www.editorji.com/lifestyle-news/food/healthy-eating-immunity-boosting-summer-foods-to-incorporate-into-your-diet-1647949499634" href="https://www.editorji.com/lifestyle-news/food/healthy-eating-immunity-boosting-summer-foods-to-incorporate-into-your-diet-1647949499634">Healthy eating: Immunity boosting summer foods to incorporate into your diet</a> SII and Bharat Biotech have been major suppliers of COVID-19 vaccines to the government so far.
Earlier in the day, he had stated that the booster dose should be made available to the public, saying it would help in protecting against the virus in future besides helping Indians overcome restrictions while travelling abroad.
In a tweet responding to a user, who highlighted difficulties faced by Indians travelling abroad who got their second dose in April 2021, <a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">Poonawalla </a>had said,&rdquo;I agree with you &amp; sympathise for the inconvenience, boosters now should be made available to the public as a CHOICE.&rdquo; He further said GoI &ldquo;has done a fantastic job, protecting our nation with two doses, but in the context of future protection and travel restrictions, boosters will be useful&rdquo;.
According to the health ministry, so far, about 96 per cent of all those above the age of 15 years in India have received at least one vaccine dose, while about 83 per cent have received both doses.
More than 2.4 crore precaution doses have also been administered to healthcare workers, frontline workers and those aged above 60 years. Besides, 45 per cent of beneficiaries in the 12-14 years age group have received the first dose, the ministry said.
The ongoing free COVID-19 inoculation programme through government vaccination centres for the first and the second dose to the eligible population as well as the precaution dose to healthcare workers, frontline workers and those above 60 years will be accelerated, the ministry stated.

People aged 60 years and above with co-morbidity will not be required to produce or submit any certificate from doctor at the time of administration of precaution dose of COVID-19 vaccine, the Centre told states and union territories on Tuesday.
Such persons are expected to obtain the advice of their doctor before deciding to avail of the precaution dose or third dose.
In a letter to states and UTs, Union Health Secretary Rajesh Bhushan said personnel to be deployed in election duty in the poll-bound states will be included in the category of frontline workers.
Eligibility of such beneficiaries for the precaution dose will be based on the date of administration of 2nd dose as recorded in the Co-WIN system -- completion of nine months i.e. 39 weeks from the date of administration of second dose -- Bhushan said.
He informed that CoWIN will send reminder messages to all those eligible for precaution dose, which will be reflected in digital vaccination certificates.
Bhushan chaired a workshop through video conference on Tuesday with all states and UTs to review the roll-out of vaccination for the age group 15-18 and precautionary third dose for vulnerable categories -- healthcare workers (HCW), frontline workers (FLW) and those in the 60-plus age group with co-morbidity.
He said only Covaxin is to be administered in the age group 15-18 years and that additional doses of the vaccine will be sent to all states and UTs.
The Union Government will share the supply schedule of Covaxin with all the states and UTs in the next few days, he said.
Potential beneficiaries can either register themselves on Co-WIN from January 1 or avail of a walk-in registration when vaccination commences from January 3. Those with a birth year of 2007 or before will be eligible for vaccination under this category, he said.
All established protocols regarding vaccination are to be followed for the 15-18 years age group, beneficiaries are to wait for half-an-hour when they will be monitored for AEFI and will be eligible for the 2nd dose only after 28 days, according to a health ministry statement.
States were informed that they have the option to designate some COVID Vaccination Centre for vaccination of the 15-18 age group exclusively which can also be reflected on Co-WIN. Dedicated CVCs would ensure that there is no confusion in administering the vaccines.
For CVCs that are intended to serve all, the states were requested to ensure separate queues and vaccination teams for the 15-18 age group.
With regards to the administration of the precautionary dose, the Union Health Secretary highlighted that nine months must have elapsed since the administration of the second dose to make the beneficiary eligible.
Drawing attention to the misinformation being propagated through various media regarding the requirement of a doctor's certificate to establish co-morbidity, he categorically emphasised that the Union government has not issued any directions on the matter and prescriptions/certificates are not mandated to be produced at the vaccination centre for administration of the precaution dose.
States and UTs were further advised to ensure the orientation of vaccinators and vaccination team members for vaccination of the 15-18 age group. States were exhorted to undertake proper planning in advance for distribution of Covaxin to identified session sites. To avoid the mixing-up of vaccines during administration, separate CVCs, separate session sites, separate queue and separate vaccination team are to be strived for.
All citizens irrespective of their income status are entitled to free COVID-19 vaccination at government vaccination centres, Bhushan said in a letter.
Those who have the ability to pay are encouraged to use private hospitals' vaccination centres. The previously declared price for each vaccine at private centre will remain applicable for these group of beneficiaries, Bhushan said.
All such healthcare workers and frontline workers who are for any reason presently registered on the Co-WIN system as citizens and are aged less than 60 years will have to get their status appropriately assigned to HCW/FLW to avail the precaution dose. However, in order to do so they must produce the employment certificate in prescribed format.
This facility will only be available at government vaccination centres in on-site mode, the letter stated.
These guidelines will come into effect from January 3 and will be reviewed from time to time.

Precaution dose for 60+ population: doctor's prescription to prove comorbidity not needed

The Centre told states and union territories on Tuesday that people aged 60 years and above with co-morbidity will not be required to produce or submit any certificate from doctor at the time of administration of precaution dose of Covid-19 vaccine.
Such persons are expected to obtain the advice of their doctor before deciding to avail of the precaution dose or third dose.
In a letter to states and UTs, Union Health Secretary Rajesh Bhushan said personnel to be deployed in election duty in the poll-bound states will be included in the category of frontline workers.
Eligibility of such beneficiaries for the precaution dose will be based on the date of administration of 2nd dose as recorded in the Co-WIN system -- completion of nine months i.e. 39 weeks from the date of administration of second dose -- Bhushan said.
He informed that CoWIN will send reminder messages to all those eligible for precaution dose, which will be reflected in digital vaccination certificates.

Precaution dose for 60+ population: doctor's prescription to prove comorbidity not needed

People aged 60 years and above with co-morbidity will not be required to produce or submit any certificate from doctor at the time of administration of<a href="https://www.editorji.com/coronavirus/more-than-9-lakh-precaution-doses-of-covid-vaccine-administered-on-first-day-1641865923508" target="_blank"> precaution dose of COVID-19 vaccine</a>, the Centre told states and union territories on Tuesday.
Such persons are expected to obtain the advice of their doctor before deciding to avail of the precaution dose or third dose.
In a letter to states and UTs, Union Health Secretary Rajesh Bhushan said personnel to be deployed in election duty in the poll-bound states will be included in the category of frontline workers.
Also read:&nbsp;<a href="https://www.editorji.com/coronavirus/explained-what-do-you-need-to-get-a-booster-dose-and-when-can-you-take-it-1640524018746" target="_blank">Explained: why do you need to get a booster dose and when can you take it</a>
Eligibility of such beneficiaries for the precaution dose will be based on the date of administration of 2nd dose as recorded in the Co-WIN system -- completion of nine months i.e. 39 weeks from the date of administration of second dose -- Bhushan said.
He informed that CoWIN will send reminder messages to all those eligible for precaution dose, which will be reflected in digital vaccination certificates.
Bhushan chaired a workshop through video conference on Tuesday with all states and UTs to review the roll-out of vaccination for the age group 15-18 and precautionary third dose for vulnerable categories -- healthcare workers (HCW), frontline workers (FLW) and those in the 60-plus age group with co-morbidity.
He said only Covaxin is to be administered in the age group 15-18 years and that additional doses of the vaccine will be sent to all states and UTs.
The Union Government will share the supply schedule of Covaxin with all the states and UTs in the next few days, he said.
Potential beneficiaries can either register themselves on Co-WIN from January 1 or avail of a walk-in registration when vaccination commences from January 3. Those with a birth year of 2007 or before will be eligible for vaccination under this category, he said.
All established protocols regarding vaccination are to be followed for the 15-18 years age group, beneficiaries are to wait for half-an-hour when they will be monitored for AEFI and will be eligible for the 2nd dose only after 28 days, according to a health ministry statement.
States were informed that they have the option to designate some COVID Vaccination Centre for vaccination of the 15-18 age group exclusively which can also be reflected on Co-WIN. Dedicated CVCs would ensure that there is no confusion in administering the vaccines.
For CVCs that are intended to serve all, the states were requested to ensure separate queues and vaccination teams for the 15-18 age group.
With regards to the administration of the precautionary dose, the Union Health Secretary highlighted that nine months must have elapsed since the administration of the second dose to make the beneficiary eligible.
Drawing attention to the misinformation being propagated through various media regarding the requirement of a doctor's certificate to establish co-morbidity, he categorically emphasised that the Union government has not issued any directions on the matter and prescriptions/certificates are not mandated to be produced at the vaccination centre for administration of the precaution dose.
States and UTs were further advised to ensure the orientation of vaccinators and vaccination team members for vaccination of the 15-18 age group. States were exhorted to undertake proper planning in advance for distribution of Covaxin to identified session sites. To avoid the mixing-up of vaccines during administration, separate CVCs, separate session sites, separate queue and separate vaccination team are to be strived for.
All citizens irrespective of their income status are entitled to free COVID-19 vaccination at government vaccination centres, Bhushan said in a letter.
Those who have the ability to pay are encouraged to use private hospitals' vaccination centres. The previously declared price for each vaccine at private centre will remain applicable for these group of beneficiaries, Bhushan said.
All such healthcare workers and frontline workers who are for any reason presently registered on the Co-WIN system as citizens and are aged less than 60 years will have to get their status appropriately assigned to HCW/FLW to avail the precaution dose. However, in order to do so they must produce the employment certificate in prescribed format.
This facility will only be available at government vaccination centres in on-site mode, the letter stated.
These guidelines will come into effect from January 3 and will be reviewed from time to time.

Congress leader Rahul Gandhi on Sunday said that the central government accepted his "suggestion" to roll out booster doses of Covid-19 vaccines in the country.
 Taking to Twitter, Rahul Gandhi said, "The central government has accepted my suggestion of a booster dose - this is a right step. The safety of vaccines and boosters will have to reach the people of the country."
On Saturday night, Prime Minister Narendra Modi announced that "precautionary doses", or booster dose of Covid-19 vaccine, would be administered to healthcare and frontline workersand people above 60 years of age with co-morbidities from January 10.
 In a tweet on December 22, Rahul Gandhi had demanded the roll out of booster doses in the country.

My suggestion accepted: Rahul Gandhi welcomes 'precaution dose' roll-out

In a tweet on December 22, Rahul Gandhi had demanded the roll out of booster doses in the country.

Congress leader Rahul Gandhi on Sunday said that the central government accepted his "suggestion" to roll out booster doses of Covid-19 vaccines in the country.
Taking to Twitter, Rahul Gandhi said, "The central government has accepted my suggestion of a booster dose - this is a right step. The safety of vaccines and boosters will have to reach the people of the country."
Also watch:<a href="https://www.editorji.com/coronavirus/pm-modi-announces-precaution-dose-for-healthcare-workers-those-above-60-with-co-morbidities-1640451253517" target="_blank">&nbsp;PM Modi announces 'precaution dose' for healthcare workers, those above 60 with co-morbidities</a>
On Saturday night, Prime Minister Narendra Modi announced that "precautionary doses", or booster doses of Covid-19 vaccine, would be administered to healthcare and frontline&nbsp;workers and&nbsp;people above 60 years of age with co-morbidities from January 10.
In a tweet on December 22, Rahul Gandhi had demanded the rollout of booster doses in the country.

Serum Institute of India has sought approval for Covishield as a booster dose from Drug Control General of India, multiple media reports quoting sources said on Wednesday. Citing adequate stock of the vaccine in the country, the Pune-based pharma giant noted that there was demand for a booster shot due to the emergence of new coronavirus variants. In an application to the DCGI, Prakash Kumar Singh, the Director, Government and Regulatory Affairs at Serum Institute of India cited that the United Kingdom has already approved the booster dose of AstraZeneca vaccine.
As the new Covid strain 'Omicron' raises alarm across the globe, Adar Poonawalla, the chief of Serum Institute of India told NDTV on Tuesday that Omicron-specific booster shots are possible. He however maintained that the focus of the government must remain to get everyone double vaccinated.

Serum seeks Covid booster shot approval after Adhar says Omicron-specific shot possible

Serum seeks Covid booster shot approval after Adar says Omicron-specific shot possible

Serum seeks Covid booster shot approval from DCGI SII says booster shot demand due to new Coronavirus&nbsp;variants Adar: possible to develop booster shot against Omicron

In an application to the DCGI, Prakash Kumar Singh, the Director, Government and Regulatory Affairs at Serum Institute of India cited that the United Kingdom&nbsp;has already approved the booster dose of AstraZeneca vaccine.

Serum Institute of India has sought approval for Covishield as a booster dose from Drug Control General of India, multiple media reports quoting sources said on Wednesday.&nbsp; Citing adequate stock of the vaccine in the country, the Pune-based pharma&nbsp;giant&nbsp;noted that there was demand for a booster shot due to the emergence of new coronavirus variants. &nbsp; In an application to the DCGI, Prakash Kumar Singh, the Director, Government and Regulatory Affairs at Serum Institute of India cited that the United Kingdom&nbsp;has already approved the booster dose of AstraZeneca vaccine. ALSO WATCH:&nbsp;<a href="https://www.editorji.com/india-news/from-vaccine-to-test-efficacy-is-the-rt-pcr-enough-1638347387982">Omicron variant: from vaccine to test efficacy, is the RT-PCR enough?</a>
As the new Covid strain 'Omicron' raises alarm across the globe, <a href="https://www.editorji.com/partner/all-india-management-association/boosting-india-s-health-security-adar-poonawalla-in-conversation-with-sanjiv-goenka-1649847929961" target="_blank">Adar Poonawalla</a>, the chief of Serum Institute of India told&nbsp;NDTV&nbsp;on Tuesday that Omicron-specific booster shots are possible. He however maintained that the focus of the government must remain to get everyone double vaccinated.

Are COVID-19 boosters the same as the original vaccines? Yes, COVID-19 boosters use the same recipe as the original shots, despite the emergence of the more contagious delta variant.
The vaccines weren't tweaked to better match delta because they're still working well.
The vaccines work by training your body to recognize and fight the spike protein that coats the coronavirus and helps it invade the body's cells. Delta's mutations fortunately weren't different enough to escape detection.
The increased protection you might get from a booster adjusted to better match the delta or other variants would be marginal, says Dr. Paul Goepfert, director of the Alabama Vaccine Research Clinic at the University of Alabama at Birmingham.
Manufacturing doses with a new formula would have also delayed the rollout of boosters.
Moderna and Pfizer are studying boosters tweaked for the delta and other variants to be ready if one's ever needed. Health authorities would have to decide if and when a vaccine formula swap would be worthwhile.
&ldquo;What we don't know,&rdquo; Goepfert noted, &ldquo;is if you have a delta vaccine compared to the regular vaccine, does it actually work better in preventing transmission or asymptomatic infection?&rdquo; The U.S. has authorized booster doses of the Pfizer, Moderna and Johnson &amp; Johnson vaccines for certain people, and a few other countries also are using boosters of those shots or other COVID-19 vaccines.

Coronavirus: How do Covid-19 boosters work and are they same as the original vaccines?

Are Covid-19 boosters the same as the original vaccines? Yes, Covid-19 boosters use the same recipe as the original shots, despite the emergence of the more contagious delta variant.
The vaccines weren't tweaked to better match delta because they're still working well.
The vaccines work by training your body to recognize and fight the spike protein that coats the coronavirus and helps it invade the body's cells. Delta's mutations fortunately weren't different enough to escape detection.
Manufacturing doses with a new formula would have also delayed the rollout of boosters.
Moderna and Pfizer are studying boosters tweaked for the delta and other variants to be ready if one's ever needed. Health authorities would have to decide if and when a vaccine formula swap would be worthwhile.

The vaccines work by training your body to recognize and fight the spike protein that coats the coronavirus and helps it invade the body's cells. Delta's mutations fortunately weren't different enough to escape detection.

Are COVID-19 boosters the same as the original vaccines? Yes, COVID-19 boosters use the same recipe as the original shots, despite the emergence of the more contagious delta variant.
The vaccines weren't tweaked to better match delta because they're still working well.
The vaccines work by training your body to recognize and fight the spike protein that coats the coronavirus and helps it invade the body's cells. Delta's mutations fortunately weren't different enough to escape detection.
The increased protection you might get from a booster adjusted to better match the delta or other variants would be marginal, says Dr. Paul Goepfert, director of the Alabama Vaccine Research Clinic at the University of Alabama at Birmingham.
Also watch | <a href="https://www.editorji.com/world-news/britain-clears-merck-s-pill-to-treat-covid-19-here-s-all-you-need-to-know-about-molnupiravir-1636029679595" target="_blank">Britain</a><a href="https://www.editorji.com/world-news/britain-clears-merck-s-pill-to-treat-covid-19-here-s-all-you-need-to-know-about-molnupiravir-1636029679595" target="_blank"> clears Merck's pill to treat Covid-19: here's all you need to know about molnupiravir</a>
Manufacturing doses with a new formula would have also delayed the rollout of boosters.
Moderna and Pfizer are studying boosters tweaked for the delta and other variants to be ready if one's ever needed. Health authorities would have to decide if and when a vaccine formula swap would be worthwhile.
&ldquo;What we don't know,&rdquo; Goepfert noted, &ldquo;is if you have a delta vaccine compared to the regular vaccine, does it actually work better in preventing transmission or asymptomatic infection?&rdquo; The U.S. has authorized booster doses of the Pfizer, Moderna and Johnson &amp; Johnson vaccines for certain people, and a few other countries also are using boosters of those shots or other COVID-19 vaccines.

booster dose vaccine in india

Categories